Structural inertia in pharmaceutical design perpetuates outdated liquid medicine use for children
Original framing: “Kids can take tablets, so why are we still giving liquid medicines?” — The Conversation - Global
The original framing omits the voices of parents and caregivers who struggle with administering liquid medicines, as well as the potential of indigenous and traditional medicine systems that offer alternative, child-friendly delivery methods. It also lacks historical context on how pharmaceutical innovation has historically neglected pediatric needs.
Medium structural omission detected in mainstream coverage.
This narrative is produced by health journalists and researchers, often for a broad public audience, but it is shaped by the dominant pharmaceutical industry paradigm. The framing serves the interests of pharmaceutical companies that benefit from the continued use of liquid medicines, which are easier to patent and produce in bulk than child-friendly alternatives.
Parents and caregivers, especially those in low-income communities, face significant challenges in administering liquid medicines. Their voices are often excluded from pharmaceutical development processes, which are dominated by corporate interests.
The continued use of liquid medicines for children is not a natural or inevitable outcome but a systemic failure rooted in pharmaceutical industry priorities, regulatory inertia, and the exclusion of marginalized voices.